NCT01831505View on ClinicalTrials.gov

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Lymphoma
Interventions
DRUG

Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them

Trial Locations (1)

98109

Seattle Cancer Care Alliance, Seattle

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Fred Hutchinson Cancer Center

OTHER

lead

Presage Biosciences

INDUSTRY

NCT01831505 - Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents | Biotech Hunter | Biotech Hunter